GENV HEM
Alternative Names: AAV8.FVa; GENV-HEMLatest Information Update: 22 Apr 2026
At a glance
- Originator University of North Carolina
- Developer GeneVentiv Therapeutics
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor V replacements; Gene transference
-
Orphan Drug Status
Yes - Haemophilia
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haemophilia
Most Recent Events
- 22 Apr 2026 GENV HEM is still in preclinical development in Haemophilia in USA (Parenteral, Infusion) (GeneVentiv Therapeutics pipeline, April 2026)
- 28 Dec 2025 No recent reports of development identified for preclinical development in Haemophilia in USA (Parenteral, Infusion)
- 29 Oct 2025 GeneVentiv Therapeutics announces intention to submit IND application to regulatory body for Haemophilia in 2026